Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMA: Abiraterone in Molecular Apocrine Breast Cancer
NCT01842321Phase 2Completed
- Sponsor
- Unicancer
- Start
- Jul 2013
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abiraterone in breast cancer, sponsored by Unicancer. Primary endpoint: Clinical Benefit Rate at 6 months. Started Jul 2013; status: completed.
02
Drugs
abiraterone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01842321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01842321.